Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days within which to revise and extend their remarks and include therein extraneous material on the subject of this Special Order. Mr. Speaker, tonight I am…
Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days within which to revise and extend their remarks and include therein extraneous material on the subject of this Special Order.
Mr. Speaker, tonight I am pleased to be joined by many of my Democratic colleagues to discuss the lack of cost control provisions in the prescription drug bill before the United States House of Representatives, H.R. 2473. In particular, I feel that it is so essential that we call
attention to the fact that this bill does nothing to use the country's bulk purchasing power on behalf of our seniors to lower the high cost of prescription drugs, the purchasing power we should be using to ensure the lowest cost of medications for our senior citizens. Quite the contrary, this bill expressly forbids it.
Like many of my colleagues, I held a sincere hope that the 108th Congress would overcome the inaction that has plagued this issue at the expense of America's senior citizens for so many years. I am extremely disappointed that the bill before the House this week not only fails to offer a structured and sound prescription drug benefit for Medicare beneficiaries, but also contains provisions that threaten the stability of the program that has provided health benefits for millions of elderly people and young adults with disabilities for the past 38 years.
While we all come to the floor with a range of grave concerns about this bill, my Democratic colleagues and I join together tonight with the united message that the House of Representatives must take action to address the rapidly rising costs of prescription drugs. H.R. 2473 not only fails to address this crisis, it actually contains a noninterference clause prohibiting the Secretary of Health and Human Services from using the bulk purchasing power of Medicare beneficiaries to negotiate for the lowest prices for senior citizens, a tactic that has proven effective in the State of Maine and is developing in Illinois and in other States.
Like many other places in the country, my home State of Rhode Island uses bulk purchasing power for seniors eligible for Medicaid to negotiate discounts for this population. America's seniors have made it clear that they want the government to assist them in obtaining their prescription drugs at a fair price.
Now, it infuriates me that in a situation where we have over 40 million people with a common and basic need, instead of taking advantage of that purchasing power to negotiate the lowest prices for the most rapidly increasing component of health care, the Federal Government is considering outlawing that practice. Amazing. The Federal Government is considering outlawing that practice.
An analysis of H.R. 2473 by the Consumers Union shows that spending on prescription drugs continues to grow. In fact, if we do not take action to curb the costs now, seniors will pay more out of pocket in 2007 with the prescription drug benefit as is currently proposed than they are paying in 2003 without it. Yet, just last week, the Committee on Energy and Commerce defeated an amendment that would have repealed the noninterference provision and allowed the Secretary of Health and Human Services to negotiate with drug companies in a similar manner to that of the Secretary of Veterans Affairs and Medicaid programs. I think that is something that is worth noting. It is already being done successfully with the Veterans Administration in providing a drug benefit to our veterans at very low cost, and the government is able to buy these at obviously a reduced cost, in making sure that our veterans get the benefit that they need, these vital medications that are so important in keeping them healthy. Yet we are going to prevent the Secretary of Health and Human Services from doing the exact same thing for the rest of the seniors in this country who are struggling to get by in paying for their prescription medications. It is simply counterintuitive.
Studies show that seniors in other industrialized countries are paying significantly less for their prescriptions than America's seniors. And, in this case, the short answer really does sum it up. It is because their governments took action to protect their interests when it comes to pricing prescription drugs. In Canada where citizens pay, on average, 50 percent less than the seniors I represent in Rhode Island, for the five most commonly prescribed drugs, the government uses the bulk purchasing power of its people to help them, and that is the way it should be. My constituents are paying 292 percent more, for example, for Prilosec than they would be in Italy where again the government uses the bulk can purchasing power of people to help them. Prices in other countries are not the result of government contributions or subsidies to drug companies; they are the result of governments using purchasing power of significant blocks of people to negotiate better prices. It is very basic.
Let us also look at another area while we are on this subject of using mechanisms to reduce drug costs. Another place where we can take action to reduce the high cost of medications is generic drugs. Last week our colleagues in the Senate took substantive measures in their Medicare reform bill to address the rapidly escalating cost of prescription drugs by easing market entry of generic drugs. In fact, their vote to do so was nearly unanimous: 94 to 1. At the same time, the House leadership, though, in a quest to push through a mere pretense of a prescription drug benefit, has failed to acknowledge that without measures to control the cost of prescription drugs, any benefit will deteriorate in value over time. America's seniors deserve better than this.
Mr. Speaker, it is amazing. The Republican leadership is so eager to subsidize the insurance companies and allow drug manufacturers to continue to exploit America's seniors in the name of the free market system, but is apparently unwilling to use that same free market system to allow the natural market force of 40 million individuals, our struggling senior citizens, to come into play.
The noninterference clause, a small section on page 250 of a 321-page bill, must be brought to light. We must draw attention to the fact that any prescription drug benefit is rendered meaningless unless action is taken to curb the out-of-control costs of drugs that people need to stay alive.
I thank my colleagues who have joined me on the floor tonight to highlight the fact that at this very moment America's seniors are making choices between taking their medications as prescribed and putting food on their tables. Just this morning I joined Dr. Sarah Fessler and the Rhode Island Academy of Family Physicians in releasing a survey showing that a third of seniors in Rhode Island are relying on physician samples for their necessary medications, and 20 percent are failing to take them as prescribed because of costs, skipping prescriptions to make them last longer, and failing to refill them. The survey reiterates what we already know: that cost is the greatest barrier to seniors taking their prescriptions.
This situation, Mr. Speaker, will not fix itself. I urge my colleagues to pay careful attention to the details of H.R. 2473 and to think critically about the effect, or the lack thereof, it will have on the seniors in their districts.
Mr. Speaker, I am pleased to yield to the distinguished gentleman from Maine (Mr. Michaud), who in his first term has taken tremendous initiative by introducing the America Rx Act under which the Federal Government would act as a pharmacy benefits manager to negotiate low prescription prices for America's seniors, and it is very appropriate that he be the first speaker this evening, and I welcome him.
Mr. Speaker, I thank the gentleman. Again, I share wholeheartedly in the statements that he has made, and I want to commend him for introducing H.R. 1694, the America Rx Act. Again, as the gentleman states, this bill establishes an America Rx program to establish fair pricing for prescription drugs for individuals without access to prescription drugs at discounted prices and, as the gentleman said, modeled after the Maine Rx program, by the Federal Government acting as a pharmacy benefits manager to negotiate the lowest prices. This approach uses the power of the free market to allow millions of American senior citizens, with no access to discount, to pool together and negotiate as one block. I cannot see what could be more basic than that. That is what certainly this Special Order is all about tonight.
I am now pleased Mr. Speaker, to yield to the gentleman from Maine (Mr. Allen), who has shown tremendous leadership on this issue by introducing the Prescription Drug Fairness for Seniors Act, which would require drug manufacturers to allow pharmacies to purchase drugs for resale to Medicare beneficiaries at the same price equivalent to the average foreign price based on the price consumers pay in six other industrialized nations.
Mr. Speaker, I thank the gentleman for his words and for his leadership on this issue. He was very eloquent tonight, as he has been so many times in the past in addressing the prescription drug problem, in fighting for our seniors. I commend him for his service in this House and for his work on this issue.
I am now, Mr. Speaker, very pleased to yield to the gentleman from Illinois (Mr. Emanuel), who has consistently worked to reduce prescription drug costs through targeted market reforms, a freshman Member of this House who has already shown his compassion for seniors and his leadership. I thank him for being here this evening.
Mr. Speaker, I thank the gentleman from Illinois for his very powerful words on this debate. I could only wish that every taxpayer in America could have heard those words tonight, along with our seniors, because it really crystallizes the debate itself, and I know we are going to be working on this together, both tomorrow, the rest of the week and until we bring this issue home. I thank the gentleman from Illinois for his comments.
That is an important aspect of this debate, the fact that taxpayer dollars have funded so much of this research, have developed these medications, and the only thanks that our taxpayers have received in return, our seniors have received in return, is high cost prescription medications that they cannot afford. That is outrageous and it is wrong.
We, as a compassionate Nation, as a determined people, have to do something about it. We have to change that and we have to make our prescription medications within reach for our seniors. No senior in America should have to make the choice between food and medication or paying their rent, not when it was their taxpayer dollars in the first place that helped develop those medications.
Mr. Speaker, I said earlier in my remarks, and each of the speakers tonight have again reiterated the argument, that we should let the free market system determine the cost of these medications, and by that, as I have said before, it means allowing our seniors to join together, use their bulk purchasing power to negotiate the lowest cost price for these medications. No prescription drug benefit should be passed by this House without that being a major component of that bill. No other insurance company, no other private insurance plan would have a prescription drug benefit without that component contained within it, and neither should one pass by this House.
Who does it benefit to pass a prescription drug benefit that does not include a component that uses the bulk purchasing power of this Nation without it being present in the bill? Is it the taxpayer? Well, certainly not because they are not getting the lowest negotiated price. Is it the seniors who are struggling to afford their medications? Well, certainly not.
It is the insurance companies, though. It is the pharmaceutical companies who do benefit: Let us keep the prescription drug prices high, let us keep the profits outrageously high, let us not be able to use bulk purchasing power that would negotiate a lowest cost price for our seniors, no, because that means that the pharmaceutical companies, the insurance companies, are out profits. That is simply wrong, Mr. Speaker, and I hope that my colleagues on both sides of the aisle will recognize this argument for what it is and do the right thing by our seniors.
Let us do what is done in Canada, in Great Britain, in Italy, in Japan, nations that for their seniors use their bulk purchasing power to bring down the high cost of medications that allows their people, their seniors to get the medications that they so readily need to stay healthy, which in many ways are wonder drugs and have become a replacement for surgery, but again, what good are they if our seniors cannot afford them? They have recognized that in Canada, in Great Britain, Italy, G-7 nations. We need to recognize that here in America.
Mr. Speaker, I thank my Democratic colleagues for joining me tonight to bring attention to this critical component of an issue that we all continue to debate throughout this week. In particular, I want to express my gratitude to the Members who have been persistent in supporting stand-alone legislation on the topic of rising prescription drug costs in recent years.
While it has yet to be brought to the floor, there is significant support in this Chamber for several pieces of legislation that would control prescription drug costs. We have heard about some of them. Tonight, we heard of the gentleman from Maine's (Mr. Allen) bill, H.R. 1400, the Prescription Drug Fairness for Seniors Act, which would significantly reduce prescription drug prices for all Medicare beneficiaries by requiring drug manufacturers to allow pharmacies to purchase medications for resale to Medicare beneficiaries at a price equivalent to the average foreign price based on the prices consumers pay in six other industrialized Nations. This legislation would provide up to a 40 percent savings on prescription drugs.
There is also bipartisan support for the Greater Access to Affordable Pharmaceuticals Act, which would speed the market entry of generic drugs by closing loopholes that are being used to lower priced competitors in the marketplace. We have heard about this this evening as well.
It is the right thing to do, to look at all of these options for controlling the high cost of prescription medications. We owe it to our seniors to look at this and do the right thing by them. We owe it to our seniors to fight for these cost controls.
Again, I ask the Republicans in this House to champion an issue that they have always championed and that is using the free market system, allowing the free market system to operate, to come to an equilibrium price. If we do that for our seniors, then everybody wins and we will have bipartisan support on that effort. It is the right thing to do. It is my sincere hope that the Republican leadership will see the light
and allow Members to offer these bills and other amendments to the Prescription Drug and Medicare Modernization Act of 2003.
I will continue to work with my Democratic colleagues to promote legislation that will provide substantial medication savings for our seniors rather than the high profit margins for drug and insurance companies.
Mr. Speaker, I thank my colleagues who have joined with us tonight in speaking on this important issue.